Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nova Eye Medical Limited (EYE.AX)
AUD0.11
-0.01 (-4.35%)
AU ASX Healthcare Medical - Devices
Address
107 Rundle Street 5067
Kent Town, SA, AU
Kent Town, SA, AU
CEO
Victor Previn
Website
nova-eye.com
IPO
1999-07-26
ISIN AU0000094252
Also trades on
Australian Securities Exchange · EYE.AX (AUD)
Other OTC · ELXMF (USD)
Description
Nova Eye Medical Limited specializes in the creation, advancement, distribution, marketing, sale, and servicing of surgical equipment dedicated to treating glaucoma. Its diverse product line features iTrack, a surgical system engineered to decrease intraocular pressure (IOP) in adult patients with open-angle glaucoma, and iTrack Advance, an innovative system promoting natural ocular fluid drainage. Furthermore, the company provides Molteno3, a glaucoma drainage device for individuals suffering from severe or intricate forms of the condition, alongside 2RT, a proprietary laser technology employed to address early to intermediate stages of age-related macular degeneration. With a presence spanning Australia, the United States, Europe, the Asia Pacific, and other international markets, the company, originally established in 1985 as Ellex Medical Lasers Limited, officially became Nova Eye Medical Limited in July 2020. Its corporate headquarters are situated in Kent Town, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.11
-0.01 (-4.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
281.1K
Beta
0.92
Float Shares
233.39M
Free Float %
81.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -5.98% | -15.38% | -26.67% | -12.00% | -16.67% | -15.38% | -58.16% | -64.14% | -88.47% | -98.92% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.11
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.42
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+25.5% ★ Q4'25: +64.8% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+15.1% Q4'25: +58.9% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-34.5% Q4'25: -14.4% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-38.4% Q4'25: -20.8% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-66.4% Q4'25: -76.6% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+21.2% Q4'25: +45.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.34× Q4'25: -0.52× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2009 actual |
Jun 2010 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 2 Rev. Ana. 1 EPS Ana. |
Jun 2027 3 Rev. Ana. 2 EPS Ana. |
Jun 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
59.25M
est: 57.29M (+3.4%)
|
48.55M
est: 51.69M (-6.1%)
|
43.08M
est: 46.77M (-7.9%)
|
54.38M
est: 55.51M (-2.0%)
|
62.76M
est: 61.58M (+1.9%)
|
73.02M
est: 70.40M (+3.7%)
|
71.81M
est: 71.80M (+0.0%)
|
79.43M
est: 82.64M (-3.9%)
|
16.14M
est: 82.00M (-80.3%)
|
12.77M
est: 84.80M (-84.9%)
|
13.39M
est: 13.85M (-3.3%)
|
13.38M
est: 13.80M (-3.1%)
|
17.03M
est: 17.90M (-4.9%)
|
23.33M
est: 22.80M (+2.3%)
|
29.27M
est: 29.90M (-2.1%)
|
32.95M
32.40M – 33.50M
+10.2% YoY
|
42.20M
39.92M – 46.38M
+28.1% YoY
|
51.20M
49.28M – 53.12M
+21.3% YoY
|
| EBITDA |
-20.74M
est: -26.21M (+20.9%)
|
6.36M
est: -23.18M (+127.4%)
|
1.73M
est: -20.97M (+108.2%)
|
3.10M
est: -24.89M (+112.4%)
|
3.95M
est: -28.16M (+114.0%)
|
7.55M
est: -32.19M (+123.5%)
|
1.51M
est: -32.83M (+104.6%)
|
-1.47M
est: -37.79M (+96.1%)
|
-4.22M
est: -37.50M (+88.7%)
|
-5.75M
est: -5.71M (-0.7%)
|
-3.67M
est: -6.34M (+42.1%)
|
-7.89M
est: -6.31M (-25.0%)
|
-14.65M
est: -8.19M (-78.9%)
|
-5.98M
est: -10.43M (+42.7%)
|
-8.99M
est: -13.68M (+34.3%)
|
-15.07M
-15.32M – -14.82M
-10.2% YoY
|
-19.30M
-21.22M – -18.26M
-28.1% YoY
|
-23.42M
-24.30M – -22.54M
-21.3% YoY
|
| EBIT |
-22.59M
est: -32.96M (+31.4%)
|
3.95M
est: -29.14M (+113.6%)
|
412.0K
est: -26.37M (+101.6%)
|
2.32M
est: -31.30M (+107.4%)
|
2.71M
est: -35.41M (+107.7%)
|
4.39M
est: -40.48M (+110.8%)
|
-1.62M
est: -41.28M (+96.1%)
|
-5.06M
est: -47.52M (+89.4%)
|
-5.25M
est: -47.15M (+88.9%)
|
-7.19M
est: -6.77M (-6.2%)
|
-5.18M
est: -7.96M (+34.9%)
|
-9.70M
est: -7.94M (-22.2%)
|
-16.95M
est: -10.30M (-64.6%)
|
-8.97M
est: -13.11M (+31.6%)
|
-11.25M
est: -17.20M (+34.6%)
|
-18.95M
-19.27M – -18.64M
-10.2% YoY
|
-24.27M
-26.68M – -22.96M
-28.1% YoY
|
-29.45M
-30.55M – -28.35M
-21.3% YoY
|
| Net Income |
-22.62M
est: 7.74M (-392.0%)
|
3.82M
est: 9.54M (-60.0%)
|
-816.0K
est: 1.51M (-154.2%)
|
788.0K
est: 3.26M (-75.9%)
|
1.68M
est: 2.24M (-25.0%)
|
3.03M
est: 2.86M (+5.8%)
|
-894.0K
est: -2.11M (+57.7%)
|
-5.07M
est: -8.40M (+39.6%)
|
-6.66M
est: -4.51M (-47.6%)
|
-6.99M
est: -6.17M (-13.4%)
|
-4.36M
est: -6.04M (+27.9%)
|
-7.50M
est: -11.20M (+33.1%)
|
-15.29M
est: -17.80M (+14.1%)
|
-8.79M
est: -11.54M (+23.8%)
|
-9.06M
est: -7.72M (-17.3%)
|
-4.02M
-4.29M – -3.76M
+47.9% YoY
|
333.3K
-3.30M – 1.32M
+108.3% YoY
|
2.23M
1.03M – 3.42M
+567.8% YoY
|
| SGA |
18.35M
est: 55.16M (-66.7%)
|
16.37M
est: 48.78M (-66.4%)
|
13.68M
est: 44.14M (-69.0%)
|
16.57M
est: 52.39M (-68.4%)
|
18.77M
est: 59.26M (-68.3%)
|
25.61M
est: 67.75M (-62.2%)
|
27.13M
est: 48.31M (-43.8%)
|
40.64M
est: 55.07M (-26.2%)
|
18.47M
est: 78.92M (-76.6%)
|
10.62M
est: 47.91M (-77.8%)
|
13.21M
est: 13.33M (-0.9%)
|
17.40M
est: 13.29M (+31.0%)
|
21.87M
est: 17.23M (+26.9%)
|
14.82M
est: 21.95M (-32.5%)
|
17.77M
est: 28.79M (-38.3%)
|
31.72M
31.19M – 32.25M
+10.2% YoY
|
40.63M
38.43M – 44.66M
+28.1% YoY
|
49.29M
47.45M – 51.14M
+21.3% YoY
|
| EPS |
-0.30
est: 0.03 (-1,058.2%)
|
0.05
est: 0.04 (+17.2%)
|
-0.01
est: 0.01 (-265.0%)
|
0.01
est: 0.01 (-44.4%)
|
0.02
est: 0.01 (+72.2%)
|
0.03
est: 0.01 (+139.3%)
|
-0.01
est: -0.01 (+11.2%)
|
-0.04
est: -0.03 (-11.2%)
|
-0.05
est: -0.02 (-147.5%)
|
-0.05
est: -0.01 (-684.9%)
|
-0.03
est: -0.02 (-20.7%)
|
-0.05
est: -0.05 (-11.5%)
|
-0.10
est: -0.07 (-32.7%)
|
-0.04
est: -0.05 (+7.6%)
|
-0.04
est: -0.03 (-17.2%)
|
-0.02
-0.02 – -0.02
+48.8% YoY
|
0.00
-0.01 – 0.01
+75.0% YoY
|
0.01
0.00 – 0.01
+325.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.53M
OE per share TTM
-0.02
Owner's Yield
-17.65%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
29.2%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-37.4K
Shares Outstanding
284.87M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas H. Spurling FRACI FTSE | MD & Executive Director | 298.0K | male |
| Victor Previn | Founder & Chairman | 255.6K | male |
| Michael Southard | Executive Director | 61.8K | male |
| Kate Hunt | Chief Commercial Officer | — | female |
| Kimberley Menzies | Chief Financial Officer | — | female |
| Joaquin V. Wolff | President of Ellex iTrack | — | male |
| Simon Jeremy Newton Gray | Company Secretary | — | male |
| Mark Flynn | Investor Relations | — | — |
| Joe Bankovich | President of Global Sales | — | male |
| Jordan Possingham | Financial Controller | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EYE.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
